LifeVantage Corp

LifeVantage Corp (LFVN) Stock Analysis

$6.230

-0.098 (-1.58%)At close

Loading chart…
High
6.440
Open
6.210
VWAP
6.29
Vol
62.63K
Mkt Cap
82.81M
Low
6.210
Amount
394.18K
EV/EBITDA, TTM
7.18

LifeVantage Corporation is an activation company, which is engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics. The Company’s line of scientifically validated activators includes the flagship Protandim family of products, TrueScience Liquid Collagen, the newest MindBody GLP-1 System, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System , as well as AXIO nootropic energy drink mixes, the full TrueScience line of skin and hair care products, and Petandim, a pet supplement formulated to combat oxidative stress in dogs. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand and Singapore.

AI analysis of LifeVantage Corp (LFVN)

hold

LifeVantage Corp is currently not a strong buy due to its recent performance and outlook. The current price is $6.355, with a significant 23.1% revenue decline reported for Q4 2026. Although the stock has a forward P/E of 37.45, indicating potential for growth, the recent revenue drop and a high short interest of 28.46% suggest market skepticism. The main risk is the declining revenue trend, which could further impact investor confidence.

Valuation Metrics

The current forward P/E ratio for LifeVantage Corp (LFVN) is 37.45, compared to its 5-year average forward P/E of 14.20.

Forward P/E

Strongly Overvalued
5Y Average P/E
14.20
Current P/E
37.45
Overvalued
25.22
Undervalued
3.19

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
5.28
Current EV/EBITDA
7.18
Overvalued
7.95
Undervalued
2.61

Forward P/S

Fair
5Y Average P/S
0.44
Current P/S
0.45
Overvalued
0.64
Undervalued
0.23

Alphio AI Price Scenarios for LFVN

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%LFVN

$16.23

Scenario price

B

Base

Base · 50%LFVN

$13.81

Scenario price

B

Bear

Bear · 25%LFVN

$12.31

Scenario price

Events Timeline

2026-08-27 (ET)

20:00:00

Nvidia's Strong Earnings Boost Tech Stocks

16:30:00

LifeVantage Q4 Revenue at $42.38M, Below Consensus

2026-06-29 (ET)

09:00:00

KULR Technology Group Borrow Rate Increases to 61.61%

2026-06-26 (ET)

09:00:00

KULR Technology Group Borrow Rate Increases to 65.52%

2026-06-24 (ET)

09:00:00

Significant Increases in Borrow Rates for Liquid Options

News

LFVN FAQ — answered by Alphio AI

LifeVantage Corporation is an activation company, which is engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics. The Company’s line of scientifically validated activators includes the flagship Protandim family of products, TrueScience Liquid Collagen, the newest MindBody GLP-1 System, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System , as well as AXIO nootropic energy drink mixes, the full TrueScience line of skin and hair care products, and Petandim, a pet supplement formulated to combat oxidative stress in dogs. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand and Singapore. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

LifeVantage Corp is currently not a strong buy due to its recent performance and outlook. The current price is $6.355, with a significant 23.1% revenue decline reported for Q4 2026. Although the stock has a forward P/E of 37.45, indicating potential for growth, the recent revenue drop and a high short interest of 28.46% suggest market skepticism. The main risk is the declining revenue trend, which could further impact investor confidence.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started